Skip to content Skip to footer
Subscribe Now
NEWS

Inocras and AimedBio Collaborate on Precision Oncology and ADC Development

Shots: Inocras and AimedBio have partnered to integrate Inocras’ whole-genome sequencing (WGS) platform into AimedBio’s ADC clinical programs, alongside AimedBio’s strategic equity investment in Inocras As per the deal, AimedBio will use Inocras’ WGS, cancer intelligence platform, & multi-omics analyses across its ADC trials to enable biomarker discovery, patient selection, and novel target identification The…
July 2, 2026

Read more

THOUGHTSPOT

Whole-genome sequencing meets real-world outcomes: what 1,364 breast cancer genomes reveal about treatment response

Author: Jehee Suh, CEO, Inocras Breast cancer is not one disease. It’s a set of biologically distinct malignancies that differ by subtype, clinical behavior, and most importantly, how patients respond to therapy. Over the past two decades, oncology has made real progress by aligning treatment to a handful of established biomarkers (ER/PR, HER2, BRCA1/2). Despite…
March 3, 2026

Read more